THOMAS MONATH to Vaccination
This is a "connection" page, showing publications THOMAS MONATH has written about Vaccination.
Connection Strength
1.858
-
Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines. 2012 Apr; 11(4):427-48.
Score: 0.268
-
Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine. 2008 Jan 24; 26(4):581-8.
Score: 0.198
-
rVSV?G-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model. Viruses. 2025 Feb 28; 17(3).
Score: 0.164
-
Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep. 2002 Nov 08; 51(RR-17):1-11; quiz CE1-4.
Score: 0.140
-
A short history of Lassa fever: the first 10-15 years after discovery. Curr Opin Virol. 2019 08; 37:77-83.
Score: 0.111
-
Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med. 1998 Dec 21; 188(12):2277-88.
Score: 0.107
-
Does restricted distribution limit access and coverage of yellow fever vaccine in the United States? Emerg Infect Dis. 1998 Oct-Dec; 4(4):698-702.
Score: 0.105
-
Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect Immun. 1998 Jun; 66(6):2879-86.
Score: 0.103
-
Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins. Infect Immun. 1997 Oct; 65(10):4288-98.
Score: 0.098
-
Yellow fever vaccine supply: a possible solution. Lancet. 2016 Apr 16; 387(10028):1599-600.
Score: 0.089
-
Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria. Am J Trop Med Hyg. 1993 Feb; 48(2):274-99.
Score: 0.071
-
Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009 Oct 09; 27(43):5974-81.
Score: 0.056
-
Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg. 2005 Feb; 72(2):189-97.
Score: 0.041
-
Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil. Microbiol Spectr. 2024 May 02; 12(5):e0370323.
Score: 0.038
-
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003 Oct 15; 188(8):1213-30.
Score: 0.037
-
High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission. Emerg Microbes Infect. 2021 Dec; 10(1):651-663.
Score: 0.033
-
Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect Immun. 2000 May; 68(5):2775-82.
Score: 0.029
-
Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine. 1999 Apr 09; 17(15-16):1869-82.
Score: 0.027
-
Immunization against natural Helicobacter pylori infection in nonhuman primates. Infect Immun. 1998 Sep; 66(9):4340-6.
Score: 0.026
-
Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ. 2017 Jun 19; 189(24):E819-E827.
Score: 0.024
-
The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis. 2011 Aug; 11(8):622-32.
Score: 0.016
-
Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination. J Infect Dis. 2011 Feb 15; 203(4):513-22.
Score: 0.015
-
Arbovirus investigations in Argentina, 1977-1980. IV. Serologic surveys and sentinel equine program. Am J Trop Med Hyg. 1985 Sep; 34(5):966-75.
Score: 0.011
-
Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun. 2003 Mar; 71(3):1608-10.
Score: 0.009
-
Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine. 2002 Dec 13; 21(3-4):194-201.
Score: 0.009
-
Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology. 2001 Nov 25; 290(2):309-19.
Score: 0.008
-
Indirect fluorescent antibody test for the diagnosis of yellow fever. Trans R Soc Trop Med Hyg. 1981; 75(2):282-6.
Score: 0.008
-
Yellow fever in the Gambia, 1978--1979: epidemiologic aspects with observations on the occurrence of orungo virus infections. Am J Trop Med Hyg. 1980 Sep; 29(5):912-28.
Score: 0.008
-
Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun. 1999 Feb; 67(2):527-38.
Score: 0.007